cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1651Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMОсобенности клинической фармакологии ацетилсалициловой кислоты как антитромботического препаратаClinical pharmacology of acetylsalicylic acid as an anti-thrombotic agentРафальскийВ. В.RafalskyV. V.

Профессор кафедры экономики и управления фармации

Смоленск

Smolensk

v.rafalskiy@mail.ruКриковаА. В.KrikovaA. V.

Заведующая этой кафедры

Смоленск

Smolensk

БагликовА. Н.BaglikovA. N.

Аспирант

Смоленск

Smolensk

ГОУ ВПО Смоленская государственная медицинская академия РосздраваРоссияSmolensk state Medical AcademyRussian Federation20090101197087102107Copyright © Рафальский В.В., Крикова А.В., Багликов А.Н., 19701970Рафальский В.В., Крикова А.В., Багликов А.Н.Rafalsky V.V., Krikova A.V., Baglikov A.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1651

В настоящее время ацетилсалициловую кислоту (АСК) используют для профилактики сердечно-сосудистых осложнений. Как профилактическое средство АСК имеет фармакокинетические и фармакодинамические особенности, которые зависят от вида лекарственной формы препарата. Максимальная эффективность АСК наблюдается при назначении низких доз – 75-150 мг/сут. Основной нежелательной реакцией (НР) АСК, применяемой для профилактики, является гастротоксичность. Путями профилактики последней служит: использование низких доз АСК, учет факторов риска со стороны пациента и выбор оптимальной лекарственной формы. Для лечения и профилактики НР со стороны желудочнокишечного тракта (ЖКТ) оправдано применение ингибиторов протонной помпы. Прием АСК в комбинации с антацидами не снижает гастротоксичность АСК. При длительном применении кишечнорастворимых форм АСК реже отмечаются эрозивно-язвенные поражения слизистой верхних отделов ЖКТ, развитие изжоги, болевого синдрома, чем при применении обычного АСК.

Currently, acetylsalicylic acid (ASA) is one of the main medications in cardiovascular prevention. Preventive ASA therapy has some specific pharmacokinetic and pharmacodynamic features, also depending on the medication form. The maximal ASA effectiveness is observed for low doses of 75-150 mg/d. The main adverse effect (AE) of preventive ASA therapy is gastro-toxicity, which could be reduced by prescribing low ASA doses, being aware of other risk factors, and choosing optimal medication forms. Gastro-intestinal (GI) AE could also be prevented and treated with proton pump inhibitors, while antacids do not reduce ASA gastro-toxicity. Comparing to standard ASA forms, intestine-soluble forms are characterised by lower risk of gastric ulcers and erosions, heartburn, and pain symptoms.

ацетилсалициловая кислотапрофилактикасердечно-сосудистые заболеванияAcetylsalicylic acidpreventioncardiovascular diseaseReferencesРумянцева Д.О., Кокурина Е.В., Байбуртский Ф.С. Клиническая фармакокинетика и метаболизм ацетилсалициловой кислоты. Современное состояние проблемы. Экспер клин фармакол 1998; 61: 76-80.Румянцева Д.О., Кокурина Е.В., Байбуртский Ф.С. Клиническая фармакокинетика и метаболизм ацетилсалициловой кислоты. Современное состояние проблемы. Экспер клин фармакол 1998; 61: 76-80.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.Drug facts and compariton, 2007 Edition. St. Louis Missouri, USA, Wolter Kluwer Health, 2007.Drug facts and compariton, 2007 Edition. St. Louis Missouri, USA, Wolter Kluwer Health, 2007.Aalykke C, Lauritsen JM, Hallas J, et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal antiinflammatory drugs: a case-control study. Gastroenterology 1999; 116: 1305-9.Aalykke C, Lauritsen JM, Hallas J, et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal antiinflammatory drugs: a case-control study. Gastroenterology 1999; 116: 1305-9.Ali M, McDonald JW, Thiessen JJ, Coates PE. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 1980; 11: 9-13.Ali M, McDonald JW, Thiessen JJ, Coates PE. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 1980; 11: 9-13.Angiolillo DJ, Kastrati A, Simon DI. Clinical guide to the use of antithrombotic drugs in coronary artery disease. London, Informa Healthcare, 2008.Angiolillo DJ, Kastrati A, Simon DI. Clinical guide to the use of antithrombotic drugs in coronary artery disease. London, Informa Healthcare, 2008.Bae SK, Seo KA, Jung EJ, et al. Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed Chromatogr 2008; 22: 590-5.Bae SK, Seo KA, Jung EJ, et al. Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed Chromatogr 2008; 22: 590-5.Benedek I, Joshi A, Pieniaszek H, et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35: 1181-6.Benedek I, Joshi A, Pieniaszek H, et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35: 1181-6.Bjorck L, Rosengren A, Bennett K, et al. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J 2009; 30: 1046-56.Bjorck L, Rosengren A, Bennett K, et al. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J 2009; 30: 1046-56.Bochner F, Siebert DM, Rodgers SE, et al. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb Haemost 1989; 61: 211-6.Bochner F, Siebert DM, Rodgers SE, et al. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb Haemost 1989; 61: 211-6.Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review. JAMA 2007; 297: 2018-24.Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review. JAMA 2007; 297: 2018-24.Capewell S, O’Flaherty M, Ford ES, Critchley JA. Potential reductions in United States coronary heart disease mortality by treating more patients. Am J Cardiol 2009; 103: 1703-9.Capewell S, O’Flaherty M, Ford ES, Critchley JA. Potential reductions in United States coronary heart disease mortality by treating more patients. Am J Cardiol 2009; 103: 1703-9.Cole H, Liew, Murray, Hawkey, Heptinstall. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Alimentary Pharmacology & Therapeutics 1999; 13: 187-93.Cole H, Liew, Murray, Hawkey, Heptinstall. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Alimentary Pharmacology & Therapeutics 1999; 13: 187-93.Cullen DJ, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41: 459-62.Cullen DJ, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41: 459-62.Dammann B, Wolf. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Alimentary Pharmacology & Therapeutics 1999; 13: 1109-14.Dammann B, Wolf. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Alimentary Pharmacology & Therapeutics 1999; 13: 1109-14.Dietz R, Rauch B. Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft f r Kardiologie – Herzund Kreislaufforschung (DGK). Z Kardiol 2003; 92: 501-21.Dietz R, Rauch B. Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft f r Kardiologie – Herzund Kreislaufforschung (DGK). Z Kardiol 2003; 92: 501-21.Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52: 563-71.Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52: 563-71.Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of doserelated effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-64.Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of doserelated effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-64.Hart J, Hawkey CJ, Lanas A, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther 2009; 30:815-22.Hart J, Hawkey CJ, Lanas A, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther 2009; 30:815-22.Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirininduced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77-83.Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirininduced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77-83.Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Nat Acad Scien USA 1987; 84: 1417-20.Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Nat Acad Scien USA 1987; 84: 1417-20.Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirinassociated major upper-gastrointestinal bleeding with entericcoated or buffered product. Lancet 1996; 348: 1413-6.Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirinassociated major upper-gastrointestinal bleeding with entericcoated or buffered product. Lancet 1996; 348: 1413-6.Konturek SJ. Mechanisms of gastroprotection. Scand J Gastroenterol Suppl 1990; 174: 15-28.Konturek SJ. Mechanisms of gastroprotection. Scand J Gastroenterol Suppl 1990; 174: 15-28.Kubler W, Darius H. Primäre Prävention der koronaren Herzkrankheit mit Aspirin. Z Kardiol 2005; 93: 66-73.Kubler W, Darius H. Primäre Prävention der koronaren Herzkrankheit mit Aspirin. Z Kardiol 2005; 93: 66-73.Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther 2006; 24: 897-908.Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther 2006; 24: 897-908.Lanas A. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Dig Liver Dis 2001; 33 Suppl 2: S29-34.Lanas A. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Dig Liver Dis 2001; 33 Suppl 2: S29-34.Levy G. Clinical pharmacokinetics of salicylates: a re-assessment. Br J Clin Pharmacol 1980; 10 Suppl 2: 285S-90.Levy G. Clinical pharmacokinetics of salicylates: a re-assessment. Br J Clin Pharmacol 1980; 10 Suppl 2: 285S-90.Montgomery PR, Sitar DS. Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets. Biopharm Drug Dispos 1986; 7: 21-5.Montgomery PR, Sitar DS. Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets. Biopharm Drug Dispos 1986; 7: 21-5.Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233.Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233.Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci 1982; 27: 624-35.Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci 1982; 27: 624-35.Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219-26.Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219-26.Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95: 1218-22.Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95: 1218-22.Sullivan JL. Gastric safety and enteric-coated aspirin. Lancet 1997; 349: 431-2.Sullivan JL. Gastric safety and enteric-coated aspirin. Lancet 1997; 349: 431-2.Takada M, Fukumoto K, Shibakawa M. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs. J Clin Pharm Ther 2004; 29: 183-7.Takada M, Fukumoto K, Shibakawa M. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs. J Clin Pharm Ther 2004; 29: 183-7.Tarnawski A, Stachura J, Gergely H, Hollander D. Gastric microvascular endothelium: a major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat. Eur J Clin Invest 1990; 20: 432-40.Tarnawski A, Stachura J, Gergely H, Hollander D. Gastric microvascular endothelium: a major target for aspirin-induced injury and arachidonic acid protection. An ultrastructural analysis in the rat. Eur J Clin Invest 1990; 20: 432-40.Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103: 2465-73.Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103: 2465-73.

The authors declare that there are no conflicts of interest present.